existing contracts; our plans to pursue label expansions and improvements for BioThrax??; our ability to perform under our current development contracts with the U.S. government; our plans to expand our manufacturing facilities and capabilities, including our ability to develop and obtain regulatory approval for large-scale manufacturing of BioThrax?? in our large-scale vaccine manufacturing facil